Implementation of a Dedicated Hematopoietic Stem Cell Transplant Program for Sickle Cell Disease in Lagos, Nigeria: Challenges and Opportunities
Rattachement africain : Nigéria, us, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Comprehensive strategies are crucial for alleviating the substantial burden of sickle cell disease (SCD) in sub-Saharan Africa. Allogeneic hematopoietic stem cell transplantation (alloHSCT) offers a potentially scalable and cost-effective cure for eligible SCD patients; however, it is currently available in only seven African countries due to difficulties in implementing alloHSCT in Low- and Middle-Income Countries (LMICs). These challenges include limited and underdeveloped healthcare infrastructure, high rates of infectious diseases worsened by emerging multidrug-resistant pathogens, restricted access to effective antimicrobial agents, and the lack of advanced transplant technologies such as T-cell depletion, HLA typing laboratories, and stem cell processing facilities. The shortage of specialized supportive care and trained staff, along with inadequate access to chemotherapeutic and immunosuppressive drugs, further hampers progress. Additionally, there is no health insurance coverage for procedures like HSCT, forcing patients and their families to pay out of pocket, which makes HSCT unaffordable for many who could greatly benefit from it. Government support remains far below what is necessary to expand transplant capacity. For those who can afford it, medical tourism for HSCT outside Africa is increasing. Unfortunately, many of these patients return to environments with limited expertise and resources for post-transplant follow-up care. This article discusses the challenges faced in establishing a dedicated alloHSCT program for SCD at a tertiary hospital in Lagos, Nigeria, and explores opportunities for improvement.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Implementation of a Dedicated Hematopoietic Stem Cell Transplant Program for Sickle Cell Disease in Lagos, Nigeria: Challenges and Opportunities
- Date Crossref
- 02/01/2026
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Lagos University of Lagos, Nigéria (code pays fourni par la source)Université ou école supérieure
-
Lagos University Teaching Hospital Department of Medicine Lagos University Teaching Hospital, Nigéria (code pays fourni par la source)Établissement de santé
-
Cleen Foundation Nigéria (code pays fourni par la source)Organisation à but non lucratif
-
The University of Texas MD Anderson Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Vanderbilt University Medical Center Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
St Mary's Hospital pays non établi dans la noticeÉtablissement de santé
-
College of Medicine Department of Pediatrics University of Lagos, Nigéria (ville ou établissement reconnu, pays non nommé)Université ou école supérieure
-
Sickle Cell Foundation of Nigeria Nigéria (pays nommé en fin d’affiliation)Organisation à but non lucratif
-
Pediatric Stem Cell Transplant/Cellular Therapy pays non établi dans la noticeInstitution
-
Imperial College Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
University of Lagos (University of Lagos, Nigéria), Department of Medicine — Lagos University Teaching Hospital (Lagos University Teaching Hospital, Nigéria) et Cleen Foundation (Nigéria), avec 7 autres affiliations. Pays d’affiliation : Nigéria.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.